PDX Model Cohort
Bladder Cancer PDX Models
A bank of meticulously curated bladder cancer PDX models directly derived from patient tumors to support bladder cancer drug development research.
Summary
Champions has developed a cohort of 10* bladder cancer PDX models to support oncology pharmacology studies and drug development. These clinically relevant models are derived from patients at various stages of clinical disease, and are pretreated with standard of care therapies.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading bladder cancer cohort showcases low-passage PDX models, each reflecting key clinical characteristics, mutations, and pretreatment history.
Access a robust bank of bladder cancer PDX models with clinically relevant molecularand pathological characteristics.
Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics, and Phosphoproteomics.
Over half of the Bladder Cancer models have been pretreated, having been exposed to either standard of care therapies or BCG (bacillus Calmette-Guerin) and/or MMC (mitomycin C) therapies.